Toxoflavin, also known as PKF118-310, is primarily studied for its potential in cancer research. It functions as an inhibitor of the Wnt/β-catenin signaling pathway, which is often dysregulated in various cancers. By targeting this pathway, it shows promise in suppressing tumor growth and progression, particularly in cancers like colorectal cancer where Wnt signaling plays a critical role. Additionally, its ability to induce apoptosis in cancer cells makes it a subject of interest for developing novel anticancer therapies. Research is ongoing to explore its efficacy and mechanisms in different cancer models.